Precision Biosciences Inc [DTIL] stock is trading at $6.64, up 2.15%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The DTIL shares have gain 12.93% over the last week, with a monthly amount glided 46.58%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Precision Biosciences Inc [NASDAQ: DTIL] stock has seen the most recent analyst activity on January 10, 2025, when BMO Capital Markets upgraded its rating to a Outperform but kept the price target unchanged to $34 for it. Previously, Guggenheim started tracking the stock with Buy rating on April 30, 2024, and set its price target to $19. On June 17, 2022, BMO Capital Markets initiated with a Outperform rating and assigned a price target of $7 on the stock. William Blair downgraded its rating to a Mkt Perform. Goldman downgraded its rating to Neutral for this stock on April 03, 2020, and downed its price target to $7. In a note dated March 05, 2020, Stifel initiated a Buy rating and provided a target price of $21 on this stock.
Precision Biosciences Inc [DTIL] stock has fluctuated between $3.61 and $9.20 over the past year. Currently, Wall Street analysts expect the stock to reach $15.5 within the next 12 months. Precision Biosciences Inc [NASDAQ: DTIL] shares were valued at $6.64 at the most recent close of the market. An investor can expect a potential return of 133.43% based on the average DTIL price forecast.
Analyzing the DTIL fundamentals
Precision Biosciences Inc [NASDAQ:DTIL] reported sales of 1.26M for the trailing twelve months, which represents a drop of -99.96%. Gross Profit Margin for this corporation currently stands at 0.45% with Operating Profit Margin at -71.46%, Pretax Profit Margin comes in at -62.06%, and Net Profit Margin reading is -62.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.72, Equity is -1.53 and Total Capital is -0.94. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.86.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.26 points at the first support level, and at 5.89 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.94, and for the 2nd resistance point, it is at 7.25.
Ratios To Look Out For
For context, Precision Biosciences Inc’s Current Ratio is 5.18. As well, the Quick Ratio is 5.18, while the Cash Ratio is 4.59. Considering the valuation of this stock, the price to sales ratio is 62.12, the price to book ratio is 2.27.
Transactions by insiders
Recent insider trading involved Frankel Stanley, Director, that happened on Sep 26 ’25 when 2700.0 shares were purchased. Director, Brown Melinda completed a deal on Sep 22 ’25 to buy 1400.0 shares. Meanwhile, Chief Financial Officer Kelly John Alexander sold 14827.0 shares on Jul 03 ’25.
